Sinotherapeutics Inc. (SHA:688247)

China · Delayed Price · Currency is CNY

10.21

+0.43 (4.40%)

At close: Aug 20, 2026

-17.66% (1Y)

Market Cap	4.39B -22.9%
Revenue (ttm)	432.19M -15.1%
Net Income	43.56M -65.2%
EPS	0.10 -64.3%
Shares Out	449.00M
PE Ratio	97.16
Forward PE	n/a
Dividend	0.04 (0.35%)
Ex-Dividend Date	Jun 26, 2026

Volume	15,596,966
Open	10.17
Previous Close	9.78
Day's Range	9.90 - 10.60
52-Week Range	7.02 - 12.55
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2012

Employees 319

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688247

Full Company Profile

Financial Performance

In 2025, Sinotherapeutics's revenue was 446.57 million, a decrease of -12.71% compared to the previous year's 511.62 million. Earnings were 47.48 million, a decrease of -62.82%.

Financial Statements